SinoMab Bioscience Limited (SinoMab) is a clinical stage biopharmaceutical company that creates and develops therapeutic antibodies for the treatment of life-threatening and other debilitating diseases based on its proprietary framework-reengineering technologies. SinoMab has a rich product pipeline with initial development efforts focused on clinically validated targets; the company is aggressively pursuing a two-pronged strategy to promote its growth:

  • an in-licensing strategy for antibody candidates at more advanced development stages
  • an out-licensing strategy of its proprietary antibody framework-reengineering technology

SinoMab has a full spectrum of drug development capabilities covering antibody re-engineering, cell line development, bioprocessing, production and preclinical studies that are essential for bringing our lead candidates through clinical development. SinoMab is one of the few companies that combines proprietary, cutting edge monoclonal antibody technology with a deep understanding on the drug development processes in Asia, especially China. Headquartered in Hong Kong and with offices and manufacturing facilities in Shenzhen and Hainan, SinoMab is a private company established in 2001 by a team of antibody experts and biotechnology professionals.